Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

Use of big data in drug development for precision medicine: an update.

Qian T, Zhu S, Hoshida Y.

Expert Rev Precis Med Drug Dev. 2019;4(3):189-200. doi: 10.1080/23808993.2019.1617632. Epub 2019 May 20.

PMID:
31286058
Free PMC Article
2.

Dose and duration of aspirin use to reduce incidental hepatocellular carcinoma.

Fujiwara N, Singal AG, Hoshida Y.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30813. [Epub ahead of print]

PMID:
31206214
3.

Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma.

Baumert TF, Hoshida Y.

Viruses. 2019 May 15;11(5). pii: E441. doi: 10.3390/v11050441.

4.

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.

Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF.

Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003. [Epub ahead of print]

PMID:
30978357
5.

Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis.

Fujiwara N, Hoshida Y.

Semin Liver Dis. 2019 May;39(2):153-162. doi: 10.1055/s-0039-1681031. Epub 2019 Mar 25.

PMID:
30912093
6.

Aspirin: Does it Have a Role for Chemoprevention of Hepatocellular Carcinoma?

Marquardt P, Hoshida Y, Singal AG.

Gastroenterology. 2019 Apr;156(5):1530-1531. doi: 10.1053/j.gastro.2019.03.006. Epub 2019 Mar 5. No abstract available.

PMID:
30849312
7.

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.

Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF.

Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2.

8.

Parathyroid hormone and premature thymus ageing in patients with chronic kidney disease.

Iio K, Kabata D, Iio R, Imai Y, Hatanaka M, Omori H, Hoshida Y, Saeki Y, Shintani A, Hamano T, Isaka Y, Ando Y.

Sci Rep. 2019 Jan 28;9(1):813. doi: 10.1038/s41598-018-37511-9.

9.

[A Case of Autopsy of Sarcomatoid Carcinoma of the Penis with Metastasis to the Right Ventricle of the Heart].

Nishino A, Nagai Y, Hanai T, Uejima S, Hoshida Y.

Hinyokika Kiyo. 2018 Nov;64(11):455-458. doi: 10.14989/ActaUrolJap_64_11_455. Review. Japanese.

PMID:
30543746
10.

Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap.

Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL.

Nat Commun. 2018 Nov 23;9(1):4962. doi: 10.1038/s41467-018-07338-z.

11.

High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.

Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J.

Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12.

12.

Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.

Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC.

J Gastrointest Surg. 2019 Jan;23(1):101-111. doi: 10.1007/s11605-018-4004-6. Epub 2018 Oct 26.

13.

Molecular heterogeneity in hepatocellular carcinoma.

Zhu S, Hoshida Y.

Hepat Oncol. 2018 Sep 11;5(1):HEP10. doi: 10.2217/hep-2018-0005. eCollection 2018 Jan. No abstract available.

14.

Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis.

Ma S, Ogino S, Parsana P, Nishihara R, Qian Z, Shen J, Mima K, Masugi Y, Cao Y, Nowak JA, Shima K, Hoshida Y, Giovannucci EL, Gala MK, Chan AT, Fuchs CS, Parmigiani G, Huttenhower C, Waldron L.

Genome Biol. 2018 Sep 25;19(1):142. doi: 10.1186/s13059-018-1511-4.

15.

Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.

Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, Bates J, Sun H, Wang T, Liu H, Ray AS, Saha AK, Greenwood J, Bhat S, Harriman G, Miao W, Rocnik JL, Westlin WF, Muti P, Tsakiridis T, Harwood HJ Jr, Kapeller R, Hoshida Y, Tanabe KK, Steinberg GR, Fuchs BC.

Cell Metab. 2019 Jan 8;29(1):174-182.e5. doi: 10.1016/j.cmet.2018.08.020. Epub 2018 Sep 20.

PMID:
30244972
16.

Generic chemoprevention of hepatocellular carcinoma.

Athuluri-Divakar SK, Hoshida Y.

Ann N Y Acad Sci. 2019 Mar;1440(1):23-35. doi: 10.1111/nyas.13971. Epub 2018 Sep 17. Review.

PMID:
30221358
17.

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J.

Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9.

PMID:
30100187
18.

Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].

Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Isabel Fiel M, Goossens N, Chou HI, Hoshida Y, Friedman SL.

J Hepatol. 2018 Oct;69(4):988. doi: 10.1016/j.jhep.2018.07.010. Epub 2018 Aug 3. No abstract available.

PMID:
30082074
19.

GIGSEA: genotype imputed gene set enrichment analysis using GWAS summary level data.

Zhu S, Qian T, Hoshida Y, Shen Y, Yu J, Hao K.

Bioinformatics. 2019 Jan 1;35(1):160-163. doi: 10.1093/bioinformatics/bty529.

PMID:
30010968
20.

[A Case of Long-Term Survival in Gastric Cancer with Multiple Liver Metastases Successfully Treated by Conversion Surgery after S-1 plus Cisplatin Combination Therapy].

Tatsubayashi T, Tanishima H, Iwakura S, Tominaga T, Kimura M, Horiuchi T, Hoshida Y.

Gan To Kagaku Ryoho. 2018 Apr;45(4):676-678. Japanese.

PMID:
29650832
21.

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.

Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou HI, Hoshida Y, Friedman SL.

J Hepatol. 2018 Aug;69(2):385-395. doi: 10.1016/j.jhep.2018.03.011. Epub 2018 Mar 21. Erratum in: J Hepatol. 2018 Oct;69(4):988.

PMID:
29572095
22.

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma.

Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S.

Front Genet. 2018 Feb 2;9:2. doi: 10.3389/fgene.2018.00002. eCollection 2018.

23.

CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K.

Gut. 2018 Aug;67(8):1493-1504. doi: 10.1136/gutjnl-2017-315193. Epub 2018 Feb 6.

PMID:
29437870
24.

In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment.

Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y.

Exp Mol Med. 2018 Jan 5;50(1):e419. doi: 10.1038/emm.2017.164.

25.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

26.

Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.

Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, Spahr L, Demetter P, Sempoux C, Im GY, Saldarriaga J, Gustot T, Devière J, Thung SN, Minsart C, Sersté T, Bontempi G, Abdelrahman K, Henrion J, Degré D, Lucidi V, Rubbia-Brandt L, Nair VD, Moreno C, Deltenre P, Hoshida Y, Franchimont D.

Gastroenterology. 2018 Mar;154(4):965-975. doi: 10.1053/j.gastro.2017.10.048. Epub 2017 Nov 20.

27.

Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.

Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Nanomedicine. 2018 Feb;14(2):317-325. doi: 10.1016/j.nano.2017.11.004. Epub 2017 Nov 20.

28.

Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases.

Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J.

Exp Mol Med. 2017 Nov 17;49(11):e396. doi: 10.1038/emm.2017.213.

29.

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Fujiwara N, Friedman SL, Goossens N, Hoshida Y.

J Hepatol. 2018 Mar;68(3):526-549. doi: 10.1016/j.jhep.2017.09.016. Epub 2017 Oct 6. Review.

30.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2018 Mar;67(3):1127-1131. doi: 10.1002/hep.29509. Epub 2018 Jan 24. No abstract available.

31.

Lateral lymph node metastasis in a patient with T1 upper rectal cancer treated by lateral lymph node dissection: a case report and brief literature review.

Tanishima H, Kimura M, Tominaga T, Iwakura S, Hoshida Y, Horiuchi T.

Surg Case Rep. 2017 Aug 23;3(1):93. doi: 10.1186/s40792-017-0366-3.

32.

Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.

Sydor S, Manka P, Best J, Jafoui S, Sowa JP, Zoubek ME, Hernandez-Gea V, Cubero FJ, Kälsch J, Vetter D, Fiel MI, Hoshida Y, Bian CB, Nelson LJ, Moshage H, Faber KN, Paul A, Baba HA, Gerken G, Friedman SL, Canbay A, Bechmann LP.

Sci Rep. 2017 Aug 14;7(1):8119. doi: 10.1038/s41598-017-08680-w.

33.

Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling.

Chernyavskaya Y, Mudbhary R, Zhang C, Tokarz D, Jacob V, Gopinath S, Sun X, Wang S, Magnani E, Madakashira BP, Yoder JA, Hoshida Y, Sadler KC.

Development. 2017 Aug 15;144(16):2925-2939. doi: 10.1242/dev.147629. Epub 2017 Jul 11.

34.

MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect.

Shtraizent N, DeRossi C, Nayar S, Sachidanandam R, Katz LS, Prince A, Koh AP, Vincek A, Hadas Y, Hoshida Y, Scott DK, Eliyahu E, Freeze HH, Sadler KC, Chu J.

Elife. 2017 Jun 23;6. pii: e22477. doi: 10.7554/eLife.22477.

35.

Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.

Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y.

Clin Transl Gastroenterol. 2017 Jun 22;8(6):e101. doi: 10.1038/ctg.2017.26.

36.

Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53.

Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D.

Clin Cancer Res. 2017 Sep 15;23(18):5446-5459. doi: 10.1158/1078-0432.CCR-17-0342. Epub 2017 Jun 19.

37.

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.

Erstad DJ, Tager AM, Hoshida Y, Fuchs BC.

Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017.

38.

Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Hectors SJ, Wagner M, Bane O, Besa C, Lewis S, Remark R, Chen N, Fiel MI, Zhu H, Gnjatic S, Merad M, Hoshida Y, Taouli B.

Sci Rep. 2017 May 26;7(1):2452. doi: 10.1038/s41598-017-02706-z.

39.

Hepatic stellate cells as key target in liver fibrosis.

Higashi T, Friedman SL, Hoshida Y.

Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007. Epub 2017 May 12. Review.

40.

Sporotrichal Tenosynovitis Diagnosed Helpfully by Musculoskeletal Ultrasonography.

Shimizu T, Akita S, Harada Y, Oguro E, Okita Y, Shigesaka M, Matsuoka H, Nii T, Teshigawara S, Kudo-Tanaka E, Tsuji S, Matsushita M, Ohshima S, Hoshida Y, Hashimoto J, Saeki Y.

Intern Med. 2017;56(10):1243-1246. doi: 10.2169/internalmedicine.56.7912. Epub 2017 May 15.

41.

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.

Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM.

Eur Radiol. 2017 Nov;27(11):4472-4481. doi: 10.1007/s00330-017-4844-6. Epub 2017 Apr 24.

42.

Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature.

Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Hepatology. 2017 Oct;66(4):1344-1346. doi: 10.1002/hep.29203. Epub 2017 Aug 26. No abstract available.

43.

Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?

Goossens N, Bian CB, Hoshida Y.

Curr Hepatol Rep. 2017 Mar;16(1):64-71. doi: 10.1007/s11901-017-0336-z. Epub 2017 Feb 1.

44.

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Baumert TF, Jühling F, Ono A, Hoshida Y.

BMC Med. 2017 Mar 14;15(1):52. doi: 10.1186/s12916-017-0815-7. Review.

45.

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.

Hicks DF, Goossens N, Blas-García A, Tsuchida T, Wooden B, Wallace MC, Nieto N, Lade A, Redhead B, Cederbaum AI, Dudley JT, Fuchs BC, Lee YA, Hoshida Y, Friedman SL.

Sci Rep. 2017 Mar 3;7:42563. doi: 10.1038/srep42563.

46.

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.

Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J.

Gut. 2018 May;67(5):953-962. doi: 10.1136/gutjnl-2016-312270. Epub 2017 Feb 3.

47.

The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy.

Kim RS, Hasegawa D, Goossens N, Tsuchida T, Athwal V, Sun X, Robinson CL, Bhattacharya D, Chou HI, Zhang DY, Fuchs BC, Lee Y, Hoshida Y, Friedman SL.

Sci Rep. 2016 Dec 20;6:39342. doi: 10.1038/srep39342.

48.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

49.

The role of GATA2 in lethal prostate cancer aggressiveness.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J.

Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22. Review.

50.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.

Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14.

Supplemental Content

Loading ...
Support Center